AkaRx, Inc.

AkaRx Inc. licenses tetrac patents from Beartownpharma Inc.

AkaRx has licensed the tetrac patents for treating thyroid cancer, developing AKR-201 to suppress TSH production. The drug aims to reduce side effects of hyperthyroidism in patients with thyroid cancer

SourceAkaRx, Inc.·DateFeb 1, 2007

Positive clinical trial results of investigational thrombocytopenia agent

AkaRx Inc. presents Phase I clinical data of AKR-501, a TPO receptor agonist that mimics the effect of thrombopoietin to stimulate platelet production, with a 50% increase in platelet count in healthy volunteers. The results suggest potential for safe and effective treatment of thrombocytopenia in various diseases.

SourceAkaRx, Inc.·JournalBlood·DateDec 12, 2006